Overview

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide